Vaxcyte Inc
F:5VA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Vaxcyte Inc (5VA) under the Base Case is 6.01 EUR per share.
Compared with the current market price of 57 EUR, the stock appears
Overvalued by 89% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Vaxcyte Does
Vaxcyte is a biotechnology company that develops vaccines for serious bacterial diseases, with a main focus on pneumococcal infections. It is not a drugstore or a hospital supplier; it is a research and development company that designs vaccine candidates, tests them in studies, and works toward regulatory approval and commercialization. Its lead products are aimed at protecting babies, children, and adults from infections that can cause pneumonia, bloodstream infections, and meningitis.
- Headquarters
- United States of America US
- Employees
- 507
- IPO date
- Jun 12, 2020
Vaxcyte has no economic moat
Providers can choose among established pneumococcal vaccines from Pfizer and Merck, and Vaxcyte has not shown it can make vaccines at a lower cost. Its candidates are not yet marketed, so it has no established product or customer base to keep rivals from winning sales.
Read the full moat analysis
Earnings Waterfall
Vaxcyte Inc
What is the Intrinsic Value of one 5VA stock?
The intrinsic value for Vaxcyte Inc (5VA) under the Base Case is 6.01 EUR.
Is 5VA stock undervalued or overvalued?
Compared with the current market price of 57 EUR, the stock appears Overvalued by 89% .
